The Technical Analyst
Oric Pharmaceuticals Inc [ORIC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Oric Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
5.22% $8.07
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 543.72 mill |
| EPS: | -1.960 |
| P/E: | -4.12 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 67.38 mill |
| Avg Daily Volume: | 0.573 mill |
| RATING 2024-04-26 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.12 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.70x |
| Company: PE -4.12 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.256 (-96.83%) $-7.81 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 7.21 - 8.93 ( +/- 10.68%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-06 | Chacko Jacob | Sell | 40 000 | Common Stock |
| 2024-02-06 | Chacko Jacob | Sell | 13 958 | Common Stock |
| 2024-02-07 | Chacko Jacob | Sell | 26 042 | Common Stock |
| 2024-01-02 | Multani Pratik S | Buy | 180 000 | Stock Option (right to buy) |
| 2024-01-02 | Multani Pratik S | Buy | 30 000 | Restricted Stock Unit |
| INSIDER POWER |
|---|
| 54.32 |
| Last 99 transactions |
| Buy: 6 373 472 | Sell: 3 807 004 |
Forecast:
16:00 - $8.07
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $8.07
Forecast 2: 16:00 - $8.07
Forecast 3: 16:00 - $8.07
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.07 (5.22% ) |
| Volume | 0.394 mill |
| Avg. Vol. | 0.573 mill |
| % of Avg. Vol | 68.82 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ORIC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $12.30 | N/A | Active |
|---|
ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-04-15 16:15:00 - Press Release
Oric Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts In Phase 1b Trial Of Oric-114 In Patients With Mutated Nsclc
Initiated multiple phase 1b expansion cohorts to determine the rp2d of oric-114 in nsclc patients with egfr exon 20, her2 exon 20, or egfr atypical mutations
2024-04-08 08:00:00 - Press Release
Oric Pharmaceuticals Presents Preclinical Data On Two Programs At The 2024 American Association For Cancer Research (aacr) Annual Meeting
Oric-944, a potent and selective allosteric prc2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor prc2 inhibitors
2024-04-05 16:30:00 - Press Release
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
South san francisco, calif. and san diego, april 05, 2024 (globe newswire) -- oric pharmaceuticals, inc. (nasdaq:oric), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on april 1, 2024 (the “grant date”), oric granted a total of 84,800 non-qualified stock options and 14,400 restricted stock units to two new non-executive employees who began their employment with oric in march 2024.
2024-04-04 16:30:00 - Press Release
Oric Pharmaceuticals To Participate In Upcoming Investor Conferences
South san francisco, calif. and san diego, april 04, 2024 (globe newswire) -- oric pharmaceuticals, inc. (nasdaq: oric), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in april:
2024-03-11 16:05:00 - Press Release
Oric Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Operational Updates
Presented initial phase 1b data from three clinical programs that support potential best in class profiles, with oric-944 and oric-114 prioritized for further advancement towards registrational studies
Latest News
2024-04-04 16:30:00 - GlobeNewsWire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in April:
2024-03-26 10:56:14 - Zacks Investment Research
How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%
The mean of analysts' price targets for Oric Pharmaceuticals (ORIC) points to a 39.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-03-06 16:30:00 - GlobeNewsWire
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will present a company overview at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 a.m. ET.
2024-02-08 09:51:11 - Zacks Investment Research
Recent Price Trend in Oric Pharmaceuticals, Inc. (ORIC) is Your Friend, Here's Why
Oric Pharmaceuticals, Inc. (ORIC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
2024-01-31 16:30:00 - GlobeNewsWire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:
2024-01-23 09:51:09 - Zacks Investment Research
Oric Pharmaceuticals, Inc. (ORIC) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Oric Pharmaceuticals, Inc. (ORIC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2024-01-09 12:31:02 - InvestorPlace
Final Boarding Call: 3 Stocks Set for a Sky-High Surge
Under most financial guidance frameworks, experts advise a long-term approach, which is exactly the opposite ethos when it comes to speculative ideas for high potential stocks. Here, the emphasis centers on getting in, scalping a quick profit and getting out to advantage the next opportunity.
2024-01-02 16:30:00 - GlobeNewsWire
ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. PT.
2023-12-09 08:00:00 - Seeking Alpha
ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting
ORIC Pharma's stock has nearly doubled after positive data from its second candidate, ORIC-114, which has shown a best-in-class profile. ORIC-114 has demonstrated minimal toxicity, CNS activity, and systemic activity in patients with EGFR or HER2 exon 20 mutated non-small cell lung cancer. The drug has the potential to address the unmet need for effective CNS accessing medicines in NSCLC patients with brain metastases.
2023-12-05 09:11:09 - InvestorPlace
3 Stocks at the Forefront of Personalized Medicine Trend
In the rapidly evolving healthcare sector, the idea of personalized medicine stocks stands out, revolutionizing patient care by tailoring treatments with their individual genetic profiles. These stocks highlight the trend of focusing on genetic and molecular characteristics, promising more effective healthcare solutions.